SectorPharmaceutical
Established Date23/11/2022
Listing Date01/05/2025
ExchangeNASDAQ Stock Exchange
Full-time Employees1
Fiscal Year Ends31/12
Security TypeCommon stock
Office address12611 Hiddencreek Way, Unit C, Cerritos, CA 90703
Business
IntroductionLiminatus Pharma, Inc., a Delaware corporation, was founded on November 23, 2022. Liminatus is a preclinical stage biopharmaceutical company developing novel immunomodulatory cancer therapies. The company's candidate IBA 101 is a humanized anti-CD47 monoclonal antibody. Initial indications for next-generation CD47 checkpoint inhibitors are expected for patients with advanced solid cancers, including non-small cell lung cancer. As a leading global biopharmaceutical company, the company's vision is to develop a broad range of transformative therapies for cancer patients.
